Liver transplantation for viral hepatitis: Current status

Paul Martin, S. J. Munoz, L. S. Friedman

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Liver transplantation is now considered definitive therapy for end-stage liver disease and has been playing an increasingly important role in the management of fulminant hepatic failure. With the advent of effective immunosuppression and improved surgical techniques, high survival rates can be expected for most transplanted patients. It has become apparent, however, that transplantation for patients with viral hepatitis is associated with some unique problems because of the propensity for viral reinfection of the grafted liver. Patients with actively replicating hepatitis B viral infection pretransplantation appear to be most likely to experience clinically significant recurrent hepatitis. Recurrent hepatitis D (delta) and hepatitis C appear to be relatively less serious in the transplanted liver. Interventions to prevent or treat graft reinfection have thus far met with limited success. Further studies are needed to define more precisely which patients with viral hepatitis are likely to do poorly after liver transplantation, and to develop strategies for treating recurrent hepatitis in transplant recipients.

Original languageEnglish
Pages (from-to)409-418
Number of pages10
JournalAmerican Journal of Gastroenterology
Volume87
Issue number4
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Liver Transplantation
Hepatitis
Hepatitis D
End Stage Liver Disease
Acute Liver Failure
Liver
Virus Diseases
Hepatitis C
Hepatitis B
Immunosuppression
Survival Rate
Transplantation
Transplants
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Liver transplantation for viral hepatitis : Current status. / Martin, Paul; Munoz, S. J.; Friedman, L. S.

In: American Journal of Gastroenterology, Vol. 87, No. 4, 01.01.1992, p. 409-418.

Research output: Contribution to journalArticle

Martin, Paul ; Munoz, S. J. ; Friedman, L. S. / Liver transplantation for viral hepatitis : Current status. In: American Journal of Gastroenterology. 1992 ; Vol. 87, No. 4. pp. 409-418.
@article{b09e3791dfff4faf90515c6be851cc4f,
title = "Liver transplantation for viral hepatitis: Current status",
abstract = "Liver transplantation is now considered definitive therapy for end-stage liver disease and has been playing an increasingly important role in the management of fulminant hepatic failure. With the advent of effective immunosuppression and improved surgical techniques, high survival rates can be expected for most transplanted patients. It has become apparent, however, that transplantation for patients with viral hepatitis is associated with some unique problems because of the propensity for viral reinfection of the grafted liver. Patients with actively replicating hepatitis B viral infection pretransplantation appear to be most likely to experience clinically significant recurrent hepatitis. Recurrent hepatitis D (delta) and hepatitis C appear to be relatively less serious in the transplanted liver. Interventions to prevent or treat graft reinfection have thus far met with limited success. Further studies are needed to define more precisely which patients with viral hepatitis are likely to do poorly after liver transplantation, and to develop strategies for treating recurrent hepatitis in transplant recipients.",
author = "Paul Martin and Munoz, {S. J.} and Friedman, {L. S.}",
year = "1992",
month = "1",
day = "1",
language = "English",
volume = "87",
pages = "409--418",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Liver transplantation for viral hepatitis

T2 - Current status

AU - Martin, Paul

AU - Munoz, S. J.

AU - Friedman, L. S.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Liver transplantation is now considered definitive therapy for end-stage liver disease and has been playing an increasingly important role in the management of fulminant hepatic failure. With the advent of effective immunosuppression and improved surgical techniques, high survival rates can be expected for most transplanted patients. It has become apparent, however, that transplantation for patients with viral hepatitis is associated with some unique problems because of the propensity for viral reinfection of the grafted liver. Patients with actively replicating hepatitis B viral infection pretransplantation appear to be most likely to experience clinically significant recurrent hepatitis. Recurrent hepatitis D (delta) and hepatitis C appear to be relatively less serious in the transplanted liver. Interventions to prevent or treat graft reinfection have thus far met with limited success. Further studies are needed to define more precisely which patients with viral hepatitis are likely to do poorly after liver transplantation, and to develop strategies for treating recurrent hepatitis in transplant recipients.

AB - Liver transplantation is now considered definitive therapy for end-stage liver disease and has been playing an increasingly important role in the management of fulminant hepatic failure. With the advent of effective immunosuppression and improved surgical techniques, high survival rates can be expected for most transplanted patients. It has become apparent, however, that transplantation for patients with viral hepatitis is associated with some unique problems because of the propensity for viral reinfection of the grafted liver. Patients with actively replicating hepatitis B viral infection pretransplantation appear to be most likely to experience clinically significant recurrent hepatitis. Recurrent hepatitis D (delta) and hepatitis C appear to be relatively less serious in the transplanted liver. Interventions to prevent or treat graft reinfection have thus far met with limited success. Further studies are needed to define more precisely which patients with viral hepatitis are likely to do poorly after liver transplantation, and to develop strategies for treating recurrent hepatitis in transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=0026593764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026593764&partnerID=8YFLogxK

M3 - Article

C2 - 1553926

AN - SCOPUS:0026593764

VL - 87

SP - 409

EP - 418

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -